heparin injekció
richter gedeon nyrt. - a heparin -
heparin 25 mg kenőcs
richter gedeon nyrt. - a heparin -
heparin ca injekció
richter gedeon nyrt. - a heparin -
heparin-calcium 25.000 ne/1 ml injekció (ampullában)
richter gedeon nyrt. - heparin -
heparibene ca 20000 ne oldatos injekció
ratiopharm hungária kft. - a heparin -
dolobene gél
ratiopharm hungária kft. - a heparin - other topical products for joint and muscular pain
teva-dolobene gél
teva gyógyszergyár zrt. - a heparin; dexpanthenol; dimetil-szulfoxid -
lioton 1000 ne/g gél
a. menarini industrie farnaceutiche riunite s.r.l. - a heparin -
heparibene na 25000 ne oldatos injekció
teva gyógyszergyár zrt. - a heparin -
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrél-hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotikus szerek - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.